Keep ChatGPT and Claude, and connect Sleuth. They’ll work from a biopharma knowledge base of programs, trials, companies, and deals, with a source on every value.
On their own, ChatGPT and Claude are strong analysts without a library of strategy data. Connect Sleuth, and they work from a biopharma knowledge base instead of rebuilding each landscape from the open web.
A fast first pass from whatever pages a web search finds that day. Some of it’s wrong, and it’s difficult to tell where.
The same chat, working from every program, trial, and deal in a space, with a source on every value. In our tests, AI tools found 63% more of the landscape.
Anthropic, OpenAI, and Google each sell AI for life sciences, but each one is built for research and discovery: papers, protein structures, notebooks, and bench data. The pipelines, deals, sell-side research, and Chinese registries that strategy work runs on aren’t the focus of any of them.
Claude for Life Sciences connects it to papers, compound databases, and lab notebooks, for scientists designing experiments.
OpenAI’s life sciences model is built for biology and chemistry: reading papers, planning experiments, and analyzing lab data.
Google’s science tools connect Gemini to protein structure and genomics databases, for generating hypotheses.
A strategic decision can shift based on data you’d otherwise miss: a competitor’s program, a deal that sets the market price, a Chinese program nobody flagged. Sleuth adds those records to the same chat, matched to one record per drug, and PubMed can stay on for the papers.
150K+
drugs, by target, modality, and phase
1M+
trials, from 20 registries
400K+
companies, public and private
200K+
deals, with terms where they’re disclosed
About 22,000
Chinese programs, from Chinese-language sources
35+
sell-side research providers
With Sleuth connected
ChatGPT and Claude on their own
With Sleuth connected
Strategy, BD, and CI work: landscapes, partner and asset searches, deal comps, and indication choices.
ChatGPT and Claude on their own
Early, lab-side science: biology, chemistry, and papers.
With Sleuth connected
One knowledge base of 150K+ drugs, 400K+ companies, and 200K+ deals, matched to one record per drug.
ChatGPT and Claude on their own
Rebuilt from whatever pages a web search finds, every time you ask.
With Sleuth connected
1M+ trials from 20 registries, China’s included, linked to the same drug records as programs and deals.
ChatGPT and Claude on their own
Claude connects to ClinicalTrials.gov. Registries outside the US, China’s above all, are hit or miss.
With Sleuth connected
200K+ licensing, M&A, collaboration, and financing deals, with upfronts, milestones, and royalties where they’re disclosed.
ChatGPT and Claude on their own
Press releases and news a web search finds, where terms are often missing.
With Sleuth connected
Research from 35+ providers, included in every plan. You don’t need an account with each bank.
ChatGPT and Claude on their own
The AI labs don’t license it, and it’s paywalled.
With Sleuth connected
Sleuth reads China’s registries in Chinese and puts each of about 22,000 programs into your landscape in English.
ChatGPT and Claude on their own
ChatGPT and Claude rarely reach China’s registries, which are in Chinese.
With Sleuth connected
Open the project in Studio and click any value to see the filing, registry entry, or broker note behind it, with a confidence score. Sleuth flags the few cells worth checking.
ChatGPT and Claude on their own
Claude cites its sources, but some of what it cites is wrong, and it’s difficult to tell where.
With Sleuth connected
Turn on monitoring, and the same dataset versions up as trials, filings, and deals come in, with a change log.
ChatGPT and Claude on their own
Ask again and it starts over, so two runs can differ.
We asked Claude, ChatGPT, and Perplexity five landscape and deal questions, once on their own and once with Sleuth connected. All 15 tests found more with Sleuth, 63% more on average.
63%
more of the landscape found with Sleuth connected, on average across 15 tests
+55%
Claude
+27%
ChatGPT
+108%
Perplexity
What changed in the answers
Claude’s IL-23 landscape left out the TL1A × IL-23p19 bispecifics and the oral IL-23R drugs. With Sleuth, both were in, and its list grew 97%.
Claude marked royalty terms “not disclosed” on 52% of its deal rows. With Sleuth, 89% of rows had real terms.
ChatGPT listed CPO102 and SYSA1801 as two drugs. They’re the same CSPC ADC, and with Sleuth they became one row.
Perplexity said comprehensive partnering databases “are generally paywalled” and stopped at 18 deals. With Sleuth, it found 150% more.
A chat answer is a block of text. With Sleuth connected, the same question comes back as a dataset you can check, keep, and export.
“Which Phase III MASH programs include F4 patients and are positioned to add on to a GLP-1?”
Every program that fits, not the ten a chat has room for.
Click a cell to see the trial, filing, or broker note behind it.
Saved to your Studio account, and exported to Excel, a deck, or an interactive analysis.
On its own, Claude gives you a first draft from the open web, and it’s difficult to tell which parts are wrong. With Sleuth connected, every value is sourced and scored, so you check only the few cells Sleuth flags.
A first draft from the open web. Some of it’s wrong, and it’s difficult to tell where.
Decision-grade. Sleuth sources and scores every value, so you only look at the few flagged cells.
Production-grade. Every delivery is checked before it reaches you, so there’s nothing left for you to review.
Claude, ChatGPT, and Perplexity found 63% more of the landscape with Sleuth connected, across 15 tests.
About 1,025 China-originated drugs are approved somewhere in the world. 34 are approved in the US.
Disclosed I&I M&A reached about $325 billion across 172 deals from 2021 through August 2026.
Claude is a strong analyst without a library. Ask it for a landscape and it rebuilds one from web searches each time. It can’t reach China’s registries in Chinese or sell-side research, and it can’t match thousands of records to the same drugs the same way every run. Some of what it finds is wrong, and it’s difficult to tell where. Sleuth did that work ahead of time, and it works inside Claude, so you can keep using it.
No. Claude for Life Sciences connects Claude to the lab: papers, compound databases, and lab notebooks. The pipelines, deals, sell-side research, and Chinese registries a landscape or partner search needs aren’t in it. Sleuth adds those, and you can use both in the same chat.
Sleuth works in Copilot through Copilot Studio, the same way it works in Claude and ChatGPT. Gemini wasn’t in our benchmark. Any AI tool that supports MCP can connect to Sleuth with the server URL.
Deep research modes search more of the open web, but they still can’t reach sell-side research or China’s registries in Chinese, and they rebuild the list from scratch each time. Our benchmark ran each app at its strongest standard setting: Claude Opus 5 and GPT-5.6 Sol at high effort, and Perplexity’s Best.
Sleuth uses frontier models from several AI labs, Anthropic’s among them, and picks the one that does each step best. The difference is the knowledge base the models work from.
No. Every plan includes Sleuth in Claude, ChatGPT, and Copilot, and analysis costs the same there as in Sleuth Studio. Your AI tool calls Sleuth only when a question needs it.